| Literature DB >> 28432147 |
Alice Gutjahr1,2,3, Laura Papagno4,5, Francesco Nicoli4,5, Alain Lamoureux1, Fabienne Vernejoul1, Thierry Lioux1, Emma Gostick6, David A Price6, Gérard Tiraby1, Eric Perouzel1, Victor Appay4,5,7, Bernard Verrier2, Stéphane Paul8.
Abstract
TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8+ T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28432147 DOI： 10.4049/jimmunol.1602131
Source DB: PubMed Journal: J Immunol ISSN： 0022-1767 Impact factor: 5.422